Clinical trials: Metastatic Progressive Breast Cancer
Metastatic Breast Cancer, Lung Metastases
Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions
This study will test the investigational antibody, MEDI6469 (anti-OX40), in combination with stereotactic body radiation in breast cancer patients that have liver or lung metastases and have received systemic therapy and have…
- Conditions
- Metastatic Breast Cancer, Lung Metastases, Liver Metastases
- Trial name
- OX40 Breast (NCT01862900)
- Testing
- MEDI6469
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Providence Health & Services
Malignancy, Breast Cancer Metastatic
The Role of Stereo-tActic BoDy RadIotherApy iN Oligo-Progressive MalignanT Disease
Systemic therapy is the main treatment for patients with metastatic cancers. Oligo-progression has become a recognized entity for metastatic cancer and it is thought that a subset of cancer cells may develop heterogeneity and…
- Conditions
- Malignancy, Breast Cancer Metastatic, Genito-urinary
- Trial name
- RADIANT (NCT04122469)
- Testing
- Stereotactic Body Radiotherapy
- Where
- Canada
- Volunteers
- 130 people
- Sponsor
- University Health Network, Toronto
Breast Cancer, Metastatic Cancer
Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00227656
- Testing
- PEG-interferon alfa-2a, Capecitabine
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center